CRISPR Therapeutics AG Missed Consensus Estimates

CRISPR Therapeutics AG (CRSP) reported a loss of $1.58 per share on revenue of $0.87 million for the first quarter ended March 2025. The consensus estimate was a loss of $1.27 per share on revenue of $5.24 million. The company missed consensus estimates by 24.41% while revenue grew 71.63% on a year-over-year basis.

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.